Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
360 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Rivaroxaban in Mechanical Valves: RIMV Study
Condition: Thromboembolism
Intervention: Drug: Rivaroxaban
2 Available A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers
Condition: Document Safety for DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancer
Intervention: Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
3 Approved for marketing Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance.
Condition: Chronic Renal Failure
Intervention: Other: intradialytic physical training program
4 Temporarily not available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
5 Available Early Patient Access Treatment Use Protocol CA204-220
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
6 Available Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Condition: Congenital Hyperinsulinism
Intervention: Drug: Pasireotide
7 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
8 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
9 Temporarily not available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
10 Available Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas and Lymphoproliferative Disorders
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
11 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
12 Available Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Abemaciclib
13 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib
14 Available Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Conditions: Cholestasis;   Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven
15 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
16 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
17 Temporarily not available An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Condition: HIV
Intervention: Drug: PRO 140
18 No longer available Expanded Access to ANG1005 for Individual Patients
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Breast Cancer With Recurrent Brain Metastases;   Leptomeningeal Carcinomatosis
Intervention: Drug: ANG1005
19 Available Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Condition: Fecal Incontinence
Intervention: Device: magnetic anal sphincter augmentation for fecal incontinence
20 Available Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Condition: Non-Hodgkin's B-cell Lymphoma
Intervention: Drug: MT-3724

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years